SLC5A2 and type 2 diabetes mellitus: Sodium-glucose co-transporter 2 (SGLT2) inhibitors such as empagliflozin, canagliflozin, dapagliflozin, and sotagliflozin are used to manage glucose levels in CVD and T2DM patients.